This is a StreetInsider.com Premium Only Page

(ORPHA.CO) – Business Wire

Jun 30, 2021 08:00 AM CytRx Comments on Orphazyme’s Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C

Jun 18, 2021 04:30 PM CytRx Notes Orphazyme’s Regulatory Update from the FDA on Arimoclomol for Niemann-Pick Disease Type C

May 13, 2021 08:00 AM CytRx Comments on Quarterly Results and Year-to-Date Progress

May 7, 2021 04:00 PM CytRx Notes Topline Data From Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

Apr 1, 2021 04:30 PM CytRx Notes Orphazyme’s Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body Myositis

Mar 8, 2021 08:00 AM CytRx Highlights Orphazyme’s Momentum Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C

Mar 4, 2021 08:00 AM CytRx Highlights Orphazyme’s Appointment of New CEO Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C

Feb 11, 2021 08:00 AM CytRx is Added to the LD Micro Index

Jan 15, 2021 08:00 AM CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Patients

Dec 31, 2020 02:00 PM CytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C

Dec 22, 2020 08:00 AM CytRx Comments on Proposed Combination of ImmunityBio and NantKwest

Dec 7, 2020 08:00 AM CytRx Announces Orphazyme’s U.S. Expansion Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C

Nov 11, 2020 08:00 AM CytRx Highlights Orphazyme’s Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C

Oct 27, 2020 08:00 AM CytRx Highlights Orphazyme’s Acceleration of Pre-Launch Activities for Arimoclomol

Oct 13, 2020 08:00 AM CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio’s Expanded Phase 2 Study of Pancreatic Cancer Treatment

Oct 7, 2020 08:00 AM CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’s Pancreatic Cancer

Sep 30, 2020 08:00 AM CytRx Issues Statement Regarding Orphazyme’s Global Offering

Sep 3, 2020 04:00 PM CytRx Announces Voting Results from 2020 Annual Meeting and Issues New Investor Presentation

Aug 24, 2020 08:00 AM CytRx Announces Initiatives to Strengthen Corporate Governance and Support Strategic Priorities

Aug 13, 2020 08:00 AM CytRx’s Board of Directors Sends Important Letter to Stockholders to Expose Dissident Investor and his Misguided Campaign